Copied to clipboard!

TIM3 blockade with hypomethylating therapy restores NK and cytotoxic CD4+ T cell activity in patients with AML or MDS

Acute myeloid leukemia (AML) remains a therapeutic challenge, requiring novel combination strategies to improve patient outcomes. This study investigates the cellular and molecular dynamics of bone marrow microenvironments in patients receiving combination therapy with anti-TIM3 and decitabine within a phase Ib clinical trial (NCT03066648). By analyzing longitudinal samples, the project aims to characterize treatment response, resistance mechanisms, and microenvironmental shifts at single-cell resolution. The resulting insights provide a comprehensive framework for evaluating checkpoint inhibition combined with hypomethylating agent in AML and MDS.

Type: Transcriptome Sequencing
Archive: Federated EGA Finland Federated EGA Node

1 Dataset

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000002961	This dataset contains demultiplexed paired-end FASTQ files generated from longitudinal bone marrow aspirates. A total of 20 samples were collected from 7 patients (6 with AML and 1 with MDS) enrolled in a phase Ib clinical trial (NCT03066648) evaluating anti-TIM3 in combination with decitabine. Libraries were constructed using the 10x Genomics Chromium Single Cell 5' platform. The data consists of raw single-cell RNA sequencing outputs.	Illumina NovaSeq X	20